剂型：颗粒剂 受理号：CXZL2500030 注册分类：中药1.1类 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025年5月22日受理的紫英颗粒 临床试验申请符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意本品开展用于盆腔 炎性疾病后遗症-慢性盆腔痛的临床试验。 格隆汇8月10日丨方盛制药(603998.SH)近日，公司控股子公司广东方盛融科药业有限公司(以下简称"方 盛融科")中药创新药研发项目紫英颗粒收到国家药品监督管理局核准签发的《药物临床试验批准通知 书》。 申请事项：临床试验 药物名称：紫英颗粒 ...

Group 1 - The core point of the article is that Fangsheng Pharmaceutical's subsidiary, Fangsheng R&D, has received approval from the National Medical Products Administration for the clinical trial of its innovative traditional Chinese medicine, Ziying Granules [1] - Ziying Granules is classified as a Class 1 innovative traditional Chinese medicine and has not yet been launched in domestic or international markets as of the announcement date [1] - The product is developed based on years of clinical experience in treating pelvic inflammatory disease and is specifically aimed at alleviating chronic pelvic pain associated with pelvic inflammatory disease sequelae [1]

Group 1 - The core point of the article is that Fangsheng Pharmaceutical's subsidiary, Fangsheng R&D, has received approval from the National Medical Products Administration for clinical trials of its innovative traditional Chinese medicine, Ziying Granules [1] - Ziying Granules is classified as a Class 1 innovative traditional Chinese medicine and is developed for the treatment of chronic pelvic pain, a sequela of pelvic inflammatory disease [1] - The product is based on years of clinical experience in treating pelvic inflammatory disease and has not yet been launched in domestic or international markets [1]

Core Viewpoint - The recent legal issues surrounding Zhang Qinghua, the controlling shareholder of Fangsheng Pharmaceutical, are linked to insider trading activities that occurred between 2017 and 2018, resulting in significant financial losses for him and others involved [1][2][3]. Company Overview - Fangsheng Pharmaceutical focuses on innovative traditional Chinese medicine and was listed in 2014. Its core products address various medical fields, including cardiovascular, pediatric, musculoskeletal, gynecological, respiratory, and anti-infection treatments [1]. - As of the end of 2024, Zhang Qinghua directly holds 35.53% of Fangsheng Pharmaceutical's shares, and his investment management company holds an additional 2.08% [3]. Financial Performance - In 2024, Fangsheng Pharmaceutical reported a revenue of 1.777 billion yuan, representing a year-on-year increase of 9.15%, and a net profit attributable to shareholders of 255 million yuan, up 36.61% [4]. - For the first quarter of 2025, the company recorded a revenue of 418 million yuan, a decrease of 4.6% year-on-year, while the net profit reached 88 million yuan, an increase of 25.74% [4]. Legal Context - Zhang Qinghua's insider trading activities are associated with a major asset restructuring involving the acquisition of Haikou Qili Pharmaceutical Co., which was publicly announced in early 2018. The insider information sensitive period was from December 13, 2017, to February 4, 2018 [2]. - The China Securities Regulatory Commission (CSRC) has previously issued an administrative penalty against Zhang Qinghua for these actions, and he is now facing potential criminal charges [5]. Implications of Legal Proceedings - The legal proceedings highlight the complexities of securities law enforcement in China, where administrative penalties can precede criminal charges. The distinction between administrative violations and criminal offenses is significant, with different standards of proof required [5]. - The recent decision to grant Zhang Qinghua bail does not imply guilt but indicates ongoing legal scrutiny regarding the insider trading allegations [5].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603998 证券简称：方盛制药 公告编号：2025-066 湖南方盛制药股份有限公司 关于公司实际控制人相关事项的进展公告 张庆华先生目前未在公司担任董事、高级管理人员职务，前述事项内容仅涉及张庆华先生个人，与公司 的日常经营管理、业务开展无关，不会对公司日常经营、业务及财务状况造成影响。 公司将继续关注上述事项的进展情况，并严格按照有关法律、法规的规定和要求，及时履行信息披露义 务。公司指定的信息披露媒体为上海证券交易所网站、《上海证券报》《证券日报》《证券时报》《中 国证券报》，公司所有信息均以在上述指定媒体披露的信息为准，敬请广大投资者注意投资风险。 特此公告 湖南方盛制药股份有限公司董事会 2025年8月7日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"公司"）控股股东暨实际控制人张庆华先生因涉嫌内幕交易公司 股票，于2021年1月18日收到中国证券监督管理委员会下发的《行政处罚决定书》（[2020]111号、 [20 ...

Mergers and Acquisitions - Tengjing Technology has decided to terminate the acquisition of 100% shares of Xunke Communication due to changes in market conditions and difficulties in reaching an agreement on the transaction plan [1] Earnings Disclosure - Ganli Pharmaceutical reported a revenue of 2.067 billion yuan for the first half of 2025, representing a year-on-year increase of 57.18%, and a net profit of 604 million yuan, up 101.96% year-on-year [2] - Shangwei New Materials announced a revenue of 784 million yuan for the first half of 2025, a year-on-year increase of 12.50%, but a net profit of 29.90 million yuan, down 32.91% year-on-year [3] - SMIC reported a sales revenue of 2.209 billion USD for the second quarter of 2025, a quarter-on-quarter decrease of 1.7%, with a gross margin of 20.4%, down 2.1 percentage points quarter-on-quarter [4] Shareholding Changes - Babai Co. announced that its major shareholder, Guangzhou Yunmei Industrial Investment Partnership, plans to reduce its holdings by no more than 2% of the company's shares, equivalent to 223.08 million shares [5] - Xianheng International disclosed that its major shareholder, Goldman Sachs Asia, intends to reduce its holdings by no more than 3%, which amounts to 12.30 million shares [6] - Linuo Pharmaceutical Packaging announced that its shareholders plan to reduce their holdings by no more than 3%, totaling 697.87 million shares [7] Risk Events - Fangsheng Pharmaceutical announced that its actual controller, Zhang Qinghua, has been placed under residential surveillance starting from August 6, 2025 [8]

Mergers and Acquisitions - Tengjing Technology has decided to terminate the acquisition of 100% shares of Xunke Communication due to changes in market conditions and difficulties in reaching an agreement on the transaction plan [1] Performance Disclosure - Ganli Pharmaceutical reported a revenue of 2.067 billion yuan for the first half of 2025, representing a year-on-year increase of 57.18%, and a net profit of 604 million yuan, up 101.96% year-on-year [2] - Shunwei New Materials announced a revenue of 784 million yuan for the first half of 2025, a year-on-year increase of 12.50%, but a net profit of 29.90 million yuan, down 32.91% year-on-year [3] - SMIC reported a sales revenue of 2.209 billion USD for the second quarter of 2025, a quarter-on-quarter decrease of 1.7%, with a gross margin of 20.4%, down 2.1 percentage points quarter-on-quarter [4] Shareholding Changes - Babai Co. announced that its major shareholder, Guangzhou Yunmei Industrial Investment Partnership, plans to reduce its holdings by no more than 223.08 million shares, accounting for 2% of the total share capital [5] - Xianheng International disclosed that its major shareholder, Goldman Sachs Asia, intends to reduce its holdings by no more than 12.30 million shares, representing no more than 3% of the total shares [6] - Lino Pharmaceutical Packaging announced that its shareholders plan to reduce their holdings by no more than 697.87 million shares, accounting for 3% of the total share capital [7] Risk Events - Fangsheng Pharmaceutical announced that its actual controller, Zhang Qinghua, has been placed under residential surveillance starting from August 6, 2025 [8]

张庆华先生目前未在公司担任董事、高级管理人员职务，前述事项内容仅涉及张庆华先生个人，与公司 的日常经营管理、业务开展无关，不会对公司日常经营、业务及财务状况造成影响。 智通财经APP讯，方盛制药(603998.SH)发布公告，公司控股股东暨实际控制人张庆华先生因涉嫌内幕 交易公司股票，于2021年1月18日收到中国证券监督管理委员会下发的《行政处罚决定书》([2020]111 号、[2020]112号)。2025年8月7日，张庆华先生向公司发送《告知函》，其于2025年8月6日收到长沙市 公安局直属分局下发的《取保候审决定书》(长公直(经)取保字[2025]0750号)，因前述事项，根据相关法 律规定，决定对其取保候审，限期从2025年8月6日起算。 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-066 湖南方盛制药股份有限公司 关于公司实际控制人相关事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"公司"）控股股东 暨实际控制人张庆华先生因涉嫌内幕交易公司股票，于 2021 年 1 月 18 日收到中国证券监督管理委员会下发的《行政处罚决定 书》（[2020]111 号、[2020]112 号）（详见公司 2021-008 号公告）。 2025 年 8 月 7 日，张庆华先生向公司发送《告知函》，其于 2025 年 8 月 6 日收到长沙市公安局直属分局下发的《取保候审决定书》 （长公直（经）取保字[2025]0750 号），因前述事项，根据相关 法律规定，决定对其取保候审，限期从 2025 年 8 月 6 日起算。 张庆华先生目前未在公司担任董事、高级管理人员职务，前 述事项内容仅涉及张庆华先生个人 ...

方盛制药公告称，公司实际控制人张庆华于2025年8月6日收到长沙市公安局直属分局下发的《取保候审 决定书》，决定对其取保候审，期限从2025年8月6日起算。张庆华目前未在公司担任职务，前述事项内 容仅涉及其个人，与公司的日常经营管理、业务开展无关，不会对公司日常经营、业务及财务状况造成 影响。 ...